Cisplatin - NanoCarrier

Drug Profile

Cisplatin - NanoCarrier

Alternative Names: Cisplatin micellar nanoparticle; Micelplatin; Nanoplatin; NC-6004

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tokyo
  • Developer NanoCarrier; Orient Europharma
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Biliary cancer; Bladder cancer; Non-small cell lung cancer
  • Phase I/II Head and neck cancer

Most Recent Events

  • 06 Nov 2017 Orient Europharma in collaboration with NanoCarrier suspends patient enrolment in a phase III trial in Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Philippines, Malaysia, South Korea, Japan, Hong Kong, Singapore and Taiwan due to the effects of the cancellation of the phase I trials in Japan for combination therapy (IV) (NCT02043288)
  • 27 Oct 2017 Phase-II clinical trials in Biliary cancer (Combination therapy, In adults, In the elderly, Late-stage disease) in Bulgaria, Romania, Poland (IV) prior to 27/10/2107 (NCT02240238) (EudraCT2016-000084-16)
  • 27 Oct 2017 Phase-II clinical trials in Bladder cancer (Combination therapy, In adults, In the elderly, Late-stage disease) in Bulgaria, Romania, Poland (IV) prior to 27/10/2107 (NCT02240238) (EudraCT2016-000084-16)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top